IPO Step-Ups: Services all the way
This article was originally published in Start Up
Executive Summary
Judging by the returns to private investors, service companies win hands-down over drugs and devices.
You may also be interested in...
Can a Hippo Save the IPO Market for Life Sciences?
A group of private enterprises are working to revive the moribund IPO market for venture-backed start-ups.
Commercializing Rare Disease Therapies Is Getting Tougher
For an industry increasingly dominated by these drugs, commercial programs need to take on the risk once reserved for development.
Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition
It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?